Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 209 of the 211 references it cites were found in a registry or an index.

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases

Open access
Diz-Chaves, Yolanda, Mastoor, Zainab, Spuch, Carlos, González-Matías, Lucas C., Mallo, Federico · 2022 · International Journal of Molecular Sciences

Abstract

The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain and displays a critical role in neuroprotection and inflammation by activating the GLP-1 receptor signaling pathways. Several studies in vivo and in vitro using preclinical models of neurodegenerative diseases show that GLP-1R activation has anti-inflammatory properties. This review explores the molecular mechanistic action of GLP-1 RAS in relation to inflammation in the brain. These findings update our knowledge of the potential benefits of GLP-1RAS actions in reducing the inflammatory response. These molecules emerge as a potential therapeutic tool in treating neurodegenerative diseases and neuroinflammatory pathologies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23179583

Cites

209 of 209 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic processing of proglucagon. NTS: nucleus of the solitary tract; GRPP: glicentin-related polypeptide; IP-1: intervening peptide-1; IP-2: intervening peptide-2; GLP-1: glucagon-like peptide-1; GLP-2: glucagon-like peptide-2; MPGF: major proglucagon fragment; PCSK1: prohormone convertase 1/3; PCSK2: prohormone convertase 2. Modified from [36]. Created with Biorender.com.
Figure 1 Schematic processing of proglucagon. NTS: nucleus of the solitary tract; GRPP: glicentin-related polypeptide; IP-1: intervening peptide-1; IP-2: intervening peptide-2; GLP-1: glucagon-like peptide-1; GLP-2: glucagon-like peptide-2; MPGF: major proglucagon fragment; PCSK1: prohormone convertase 1/3; PCSK2: prohormone convertase 2. Modified from [36]. Created with Biorender.com.CC BY · PubMed Central
Figure 2 GLP-1 receptor activation induces several second messenger cell signaling pathways.
Figure 2 GLP-1 receptor activation induces several second messenger cell signaling pathways.CC BY · PubMed Central
Figure 3 Microgliosis and astrocytosis induced by neurodegenerative diseases are blocked by GLP-1 receptor activation. Abbreviatures: IL-1β: interleukin-1β; IL-12: interleukin-12; IL-23: interleukin-23; IL-33: interleukin-33; IL-6: interleukin-6; CXCL2: Chemokine (C-X-C motif) ligand 2; CCL5: CC chemokine ligand 5; CXCL4: chemokine (C-X-C motif) ligand 4; CCL2: C-C Motif Chemokine Ligand 2; BAFF: B cell–activating factor of the TNF family; CXCL-1: chemokine (C-X-C motif) ligand 1; TNF-α: Tumor necrosis factor α; NO: nitric oxide; VEGFB: Vascular Endothelial Growth Factor B; ROS: Reactive oxygen species; Cq1: complement component 1q.
Figure 3 Microgliosis and astrocytosis induced by neurodegenerative diseases are blocked by GLP-1 receptor activation. Abbreviatures: IL-1β: interleukin-1β; IL-12: interleukin-12; IL-23: interleukin-23; IL-33: interleukin-33; IL-6: interleukin-6; CXCL2: Chemokine (C-X-C motif) ligand 2; CCL5: CC chemokine ligand 5; CXCL4: chemokine (C-X-C motif) ligand 4; CCL2: C-C Motif Chemokine Ligand 2; BAFF: B cell–activating factor of the TNF family; CXCL-1: chemokine (C-X-C motif) ligand 1; TNF-α: Tumor necrosis factor α; NO: nitric oxide; VEGFB: Vascular Endothelial Growth Factor B; ROS: Reactive oxygen species; Cq1: complement component 1q.CC BY · PubMed Central
Figure 4 GLP-1 receptor activation induces an anti-inflammatory response. Abbreviatures: NFκB: Nuclear Factor kappa B; IKKK: IκB kinase kinase; IKKβ: IκB kinase β; pro-IL-1β: pro-interleukin-1β; pro-IL-18: pro-interleukin-18; ASC: Apoptosis-associated Speck-like protein containing a CARD; NEK7: NIMA Related Kinase 7; AMPK: adenosine monophosphate-activated protein kinase; SIRT1: Sirtuin 1; GSMD: Gasdermin D; IL-1β: interleukin-1β; IL-2: interleukin-2; IL-6: interleukin-6; MCP1: Monocyte chemoattractant protein 1; ICAM: Intracellular adhesion molecule-1; VCAM: Vascular cell adhesion molecule-1; NAD/NADH: Nicotinamide adenine dinucleotide. Partially Biorender. com used.
Figure 4 GLP-1 receptor activation induces an anti-inflammatory response. Abbreviatures: NFκB: Nuclear Factor kappa B; IKKK: IκB kinase kinase; IKKβ: IκB kinase β; pro-IL-1β: pro-interleukin-1β; pro-IL-18: pro-interleukin-18; ASC: Apoptosis-associated Speck-like protein containing a CARD; NEK7: NIMA Related Kinase 7; AMPK: adenosine monophosphate-activated protein kinase; SIRT1: Sirtuin 1; GSMD: Gasdermin D; IL-1β: interleukin-1β; IL-2: interleukin-2; IL-6: interleukin-6; MCP1: Monocyte chemoattractant protein 1; ICAM: Intracellular adhesion molecule-1; VCAM: Vascular cell adhesion molecule-1; NAD/NADH: Nicotinamide adenine dinucleotide. Partially Biorender. com used.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 211 references

Cited by

See all 152

Metadata

Authors
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F.
Affiliations
  • Universidade de Vigo (ES)
  • Translational Neuroscience Research Group, Galicia Sur Health Research Institute, CIBERSAM, Hospital Álvaro Cunqueiro, Bloque Técnico, Planta 2, Sala de Investigación, Estrada Clara Campoamor, 341, 36212 Vigo, Spain
Corresponding author
Diz-Chaves, Yolanda
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-08-24
Volume
23
Issue
17
Pages
9583
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4293001879
Cited by
148
References
211
Citations by year
2026: 52 · 2025: 66 · 2024: 21 · 2023: 9
FWCI
2.47
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Investigo Institutional repository of UVigo (Universidade de Vigo) (submittedVersion, cc-by)
Funders
  • European Union Grant Alehoop (H2020-BBIJTI-2019-887259, ED431G/02)
  • Xunta de Galicia (Centro singular de Investigación de Galicia accreditation 2016–2019) (H2020-BBIJTI-2019-887259, ED431G/02)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
glucagon-like peptide-1, GLP-1 receptor, neuroinflammation, neurodegenerative diseases, neuroprotection, anti-inflammatory activity, brain, GLP-1 receptor signaling, therapeutic target
MeSH terms
Glucagon-Like Peptide-1 Receptor, Brain, Humans, Inflammation, Neurodegenerative Diseases, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. https://app.cochat.ai/papers/10.3390/ijms23179583
The paper
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23179583

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.